Scientific Project Manager

Myriam Ly Le Moal

Neurosciences, Rare Diseases

“Seuls ceux qui sont assez fous pour penser qu’ils peuvent changer le monde y parviennent » Henri Dunant, Fonder of the Red Cross. This sentence is a moto for me as I put all my energy in creating game-changing synergies in research to change the future of patients affected with devastating brain disorders and rare disease conditions. My daily job is to understand how the most brilliant minds can join forces to turn ideas and intentions into actionable results and bring to our patients, in a meaningful and concrete way, the highest standards of scientific advances.”

Your role at Institut Roche and brief presentation of your professional background:

I am a Neurobiologist by training with a dual course in Business Administration from Pierre & Marie Curie University (Paris Sorbonne Univ.); I also studied Journalism and scientific communication at Paris Diderot university (Paris V). After a journey at the bench, I was research ingeneer at Inserm for some time where I touched upon the topics of big data, data analytics and data quality in the systems of Assistance Publique des Hôpitaux de Paris –on a project regrouping 83 medical centers in Ile de France-. I then joined the executive office of Institut Pasteur where I held the novel Grant Manager position. There, I was in charge of setting transformative consortia – internal, external and with the international Network of Pasteur Insitutes through the world- ith the aim to compete for international public and private grants.

I joined the Institut Roche in 2016 as a Senior Scientific Project Manager. My role since then is to deeply understand the needs of Roche R&D and the landscape of academic research in Neuroscience and rare diseases in order to create dream “win-win” projects that we trust will meaningfully benefit the patients. A collaboration is not obvious because of many external contingencies and particular considerations. My role is to remove the hurdles to make those alliances and collaborations work and ultimately deliver cutting-edge scientific knowledge, not just for the sake of creating knowledge but ultimately to benefit patients in their daily living.


My Focus at Institut Roche:

Neuroscience and rare diseases Research partnerships, alliances set up and management.

  1. Annoussamy, M., et al. (2021). “Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.” Ann Clin Transl Neurol 8(2): 359-373.
  2. Baltazar, M., et al. (2021). “”Reading the Mind in the Eyes” in Autistic Adults is Modulated by Valence and Difficulty: An InFoR Study.” Autism Res 14(2): 380-388.
  3. Amestoy, A., et al. (2021). “Visual attention and inhibitory control in children, teenagers and adults with autism without intellectual disability: results of oculomotor tasks from a 2-year longitudinal follow-up study (InFoR).” Mol Autism 12(1): 71.
  4. Lefebvre, A., et al. (2021). “Discriminant value of repetitive behaviors in families with autism spectrum disorder and obsessional compulsive disorder probands.” Autism Res 14(11): 2373-2382.
  5. Briot, K., et al. (2020). “Social Anxiety in Children and Adolescents With Autism Spectrum Disorders Contribute to Impairments in Social Communication and Social Motivation.” Front Psychiatry 11: 710.
  6. Laidi, C., et al. (2019). “Decreased Cortical Thickness in the Anterior Cingulate Cortex in Adults with Autism.” J Autism Dev Disord 49(4): 1402-1409.
  7. Bennabi, M., et al. (2019). “Persistence of dysfunctional natural killer cells in adults with high-functioning autism spectrum disorders: stigma/consequence of unresolved early infectious events?” Mol Autism 10: 22.
  8. d’Albis, M. A., et al. (2018). “Local structural connectivity is associated with social cognition in autism spectrum disorder.” Brain 141(12): 3472-3481.
  9. M. Ly, B. Delatour . Particular types of beta-amyloid oligomers are formed in Alzheimer’s disease-like physiopathological conditions Alzheimer’s and Dementia 07/2013; 9(4):P196. 17.47 Impact Factor
  10. M. Ly, C. Delarasse, B. Delatour. APPxPS1dE9 mice display neuronal dysfunction at an asymptomatic state of amloïdosis. Alzheimer’s and Dementia 07/2013; 9(4):P712. 17.47 Impact Factor
  11. S. Epelbaum, P. Lacor, M. Ly, C. Duyckaerts, B. Delatour. Acute functional and morphological impact of Aß oligomers. Alzheimer’s and Dementia 07/2012; 8(4):P297. DOI:10.1016/j.jalz.2012.05.802 · 17.47 Impact Factor
  12. Faure, L. Verret, B. Bozon, N. El Tannir El Tayara, M. Ly, F. Kober, M. Dhenain, C. Rampon, B. Delatour. (2011). Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer’s disease. Neurobiology of Aging 03/2011; 32(3) 4.85 Impact Factor
  13. M. Ly, P. Lacor, A. Krezymon, C. Rampon, B. Delatour, C. Duyckaerts. Natural history of Aßplaque formation: oligomers accumulation precedes fibrillar deposits, Alzheimer’s and Dementia 07/2011; 7(4).
  14. B. Delatour, M. Ly, C. Duyckaerts. Functional correlations of intracellular Aß peptide in transgenic mouse models Alzheimer’s and Dementia 07/2011; 7(4). 17.47 Impact Factor
  15. Delatour, M. Ly, C. Duyckaerts (2010) Aggregated versus soluble and intracellular species of the amyloid ß peptide: lessons from the APPxPS1-Ki model Alzheimer’s and Dementia 07/2010; 6(4).
  16. Le Cudennec, A. Faure, M. Ly, B. Delatour (2008). One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain and Behavior 03/2008; 7 Suppl 1:83-91.
More publications